Table 2. . Treatment discontinuation rates in clinical trials for marketed drug concentrations.
| Drug/Product | Study designation, (n) % | |||
|---|---|---|---|---|
| Cyclosporine ophthalmic emulsion 0.05% |
PROTOCOL-001 (31) |
PROTOCOL-002 (135) |
PROTOCOL-003 (158) |
Integrated (293) |
| REDACTED | (28) 20.7% | (30) 19% | (58) 19.8% | |
| Lifitegrast ophthalmic solution 5% |
OPUS-1 (293) |
OPUS-2 (360) |
OPUS-3 (355) |
Integrated (1,066) |
| (12) 4.1% | (37) 10.3% | (36) 10.1% | (85) 8.9% | |
| Varenicline solution nasal spray 0.03 mg |
ONSET-1 (48) |
MYSTIC (41) |
ONSET-2 (260) |
Integrated (349) |
| (2) 4.2% | (5) 12.2% | (9) 3.5% | (16) 4.6% | |